Josep J. Centelles

Dr. Josep J. Centelles

Departament de Bioquímica I Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Avda. Diagonal 643, 08028-Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MCMARTA CASCANTE
MARTA CASCANTE
LBLaszlo G. Boros
Laszlo G. Boros
BCBegoña Comin-Anduix
Begoña Comin-Anduix
PAPedro de Atauri
Pedro de Atauri
Josep J. CentellesJosep J. Centelles
Josep J. Centelles
PLPaul W.-N. Lee
Paul W.-N. Lee

15 November 2002 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
JTJosep Lluís Torres
Josep Lluís Torres
BVBegoña Varela
Begoña Varela
MGMaria Teresa Garcia
Maria Teresa Garcia
JCJosep Carilla
Josep Carilla
CMCecilia Matito
Cecilia Matito
RBRaül Bobet
Raül Bobet

1 October 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JBJoan Boren
Joan Boren
MCMARTA CASCANTE
MARTA CASCANTE
Silvia MarinSilvia Marin
Silvia Marin
BCBegoña Comı́n-Anduix
Begoña Comı́n-Anduix
Josep J. CentellesJosep J. Centelles
Josep J. Centelles
LBLászló G. Boros
László G. Boros
Chronic myeloid leukemia cells contain a constitutively active Bcr-Abl tyrosine kinase, the target protein of Gleevec (STI571) phenylaminopyrimidine class protein kinase inhibitor. Here we provide evidence for metabolic phenotypic changes in cultured K562 human myeloid blast cells after treatment with increasing doses of STI571 using [1,2-13C2]glucose as the single tracer and biological mass spectrometry. In response to 0.68 and 6.8 μm STI571, proliferation of Bcr-Abl-positive K562 cells showed a 57% and 74% decrease, respectively, whereas glucose label incorporation into RNA decreased by 13.4% and 30.1%, respectively, through direct glucose oxidation, as indicated by the decrease in the m1/Σmnratio in RNA. Based on the in vitro proliferation data, the IC50 of STI571 in K562 cultures is 0.56 μm. The decrease in 13C label incorporation into RNA ribose was accompanied by a significant fall in hexokinase and glucose-6-phosphate 1-dehydrogenase activities. The activity of transketolase, the enzyme responsible for nonoxidative ribose synthesis in the pentose cycle, was less affected, and there was a relative increase in glucose carbon incorporation into RNA through nonoxidative synthesis as indicated by the increase in them2/Σmn ratio in RNA. The restricted use of glucose carbons for de novo nucleic acid and fatty acid synthesis by altering metabolic enzyme activities and pathway carbon flux of the pentose cycle constitutes the underlying mechanism by which STI571 inhibits leukemia cell glucose substrate utilization and growth. The administration of specific hexokinase/glucose-6-phosphate 1-dehydrogenase inhibitor anti-metabolite substrates or competitive enzyme inhibitor compounds, alone or in combination, should be explored for the treatment of STI571-resistant advanced leukemias as well as that of Bcr-Abl-negative human malignancies.

1 August 2001 in European Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
BCBegoña Comín‐Anduix
Begoña Comín‐Anduix
JBJoan Boren
Joan Boren
SMSonia Martinez
Sonia Martinez
CMCristina Moro
Cristina Moro
Josep J. CentellesJosep J. Centelles
Josep J. Centelles
MCMARTA CASCANTE
MARTA CASCANTE
Thiamine deficiency frequently occurs in patients with advanced cancer and therefore thiamine supplementation is used as nutritional support. Thiamine (vitamin B1) is metabolized to thiamine pyrophosphate, the cofactor of transketolase, which is involved in ribose synthesis, necessary for cell replication. Thus, it is important to determine whether the benefits of thiamine supplementation outweigh the risks of tumor proliferation. Using oxythiamine (an irreversible inhibitor of transketolase) and metabolic control analysis (MCA) methods, we measured an in vivo tumour growth control coefficient of 0.9 for the thiamine‐transketolase complex in mice with Ehrlich's ascites tumour. Thus, transketolase enzyme and thiamine clearly determine cell proliferation in the Ehrlich's ascites tumour model. This high control coefficient allows us to predict that in advanced tumours, which are commonly thiamine deficient, supplementation of thiamine could significantly increase tumour growth through transketolase activation. The effect of thiamine supplementation on tumour proliferation was demonstrated by in vivo experiments in mice with the ascites tumour. Thiamine supplementation in doses between 12.5 and 250 times the recommended dietary allowance (RDA) for mice were administered starting on day four of tumour inoculation. We observed a high stimulatory effect on tumour growth of 164% compared to controls at a thiamine dose of 25 times the RDA. This growth stimulatory effect was predicted on the basis of correction of the pre‐existing level of thiamine deficiency (42%), as assayed by the cofactor/enzyme ratio. Interestingly, at very high overdoses of thiamine, ≈ 2500 times the RDA, thiamine supplementation had the opposite effect and caused 10% inhibition of tumour growth. This effect was heightened, resulting in a 36% decrease, when thiamine supplementation was administered from the 7th day prior to tumour inoculation. Our results show that thiamine supplementation sufficient to correct existing thiamine deficiency stimulates tumour proliferation as predicted by MCA. The tumour inhibitory effect at high doses of thiamine is unexplained and merits further study.

21 October 2003 in FEBS Letters
Verified
Journal Article
Closed access
Silvia MarinSilvia Marin
Silvia Marin
KCKelly Chiang
Kelly Chiang
SBSara Bassilian
Sara Bassilian
WLWai-Nang Paul Lee
Wai-Nang Paul Lee
LBLaszlo G Boros
Laszlo G Boros
MCMARTA CASCANTE
MARTA CASCANTE